Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVENTURINE: CLDN6 CAR-T in Relapsed/Refractory Germ Cell Tumors
NCT06940804Phase 2Withdrawn
- Sponsor
- BioNTech SE
- Start
- Jul 2025
- Primary completion
- Jun 2042
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
A Phase 2 trial of BNT211 in Testicular Germ Cell Tumor (TGCT), extragonadal germ cell tumor (EGGCT), sponsored by BioNTech SE. Planned start Jul 2025; status: withdrawn.
02
Drugs
BNT211
03
Conditions
Testicular Germ Cell Tumor (TGCT)extragonadal germ cell tumor (EGGCT)
Beyond the preview
Go deeper on NCT06940804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940804.